

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL HOLDINGS FOR THE THREE MONTHS ENDED 31 MARCH 2023 IN RELATION TO ISSUANCES OF MEDIUM TERM NOTES AND CORPORATE BONDS IN THE PRC

Reference is made to: (i) the announcement dated 23 June 2021 in relation to, among others, the completion of the issuance of the first tranche of medium term notes for the year of 2021 by China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly owned subsidiary of the Company; and (ii) the announcement dated 21 January 2022 in relation to, among others, the completion of the public issuance of the 2022 first tranche corporate bonds in the PRC by CR Pharmaceutical Holdings (the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

In accordance with the relevant rules and regulations in the PRC and in connection with its issuances of medium term notes and corporate bonds in the PRC, CR Pharmaceutical Holdings has published its audited report for the year ended 31 December 2022 and unaudited financial statements for the three months ended 31 March 2023 on the website of Beijing Financial Assets Exchange and has published its audited report for the year ended 31 December 2022 on the website of the Shanghai Stock Exchange.

The unaudited financial statements of CR Pharmaceutical Holdings for the three months ended 31 March 2023 (the “**Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings**”) are enclosed to this announcement for the Company’s shareholders’ information only. The Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings were prepared in Chinese and have been translated for publication in English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail. In addition, the Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company’s auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Holdings only and does not represent or provide a complete view of the operational or financial status of the Group. Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Beijing, 28 April 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
BALANCE SHEET IN ACCORDANCE WITH
THE PRC STANDARDS MARCH 2023

Adjusted to denominated currency

Unit: RMB1

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	756,874,829.13	707,909,869.06	Short-term borrowings	1,680,000,000.00	1,040,000,000.00
Held-for-trading financial assets	206,307,878.31	200,128,989.39	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	-	-
Notes receivable	-	-	Including: Notes payable	-	-
Accounts receivable	-	-	Accounts payable	-	-
Financing receivables	-	-	Receipts in advance	-	-
Prepayment	-	-	Contract liabilities	-	-
Other receivables	23,532,264,553.41	23,437,221,578.24	Staff remuneration payable	386,159,624.18	46,091,509.86
Including: Interest receivable	-	-	Including: Wages payable	-	-
Dividends receivable	5,416,748,449.32	5,416,748,449.32	Benefits payable	-	-
Inventory	-	-	Taxation payable	-	2,454,171.63
Including: Raw materials	-	-	Including: Tax payable	-	-
Goods in stock (finished products)	-	-	Other payables	10,686,777,382.27	14,348,655,903.43
Contract assets	-	-	Including: Interest payable	-	-
Assets held for sale	-	-	Dividends payable	3,507,000,000.00	3,507,000,000.00
Non-current assets due within one year	-	-	Insurance contract liabilities	-	-
Other current assets	-	10,818,810.96	liabilities held for sale	-	-
			Non-current liabilities due within one year	3,488,177,566.32	1,103,983,630.89
			Other current liabilities	-	-
Total current assets	24,495,447,260.85	24,356,079,247.65	Total current liabilities	16,241,114,572.77	16,541,185,215.81
Non-current assets:			Non-current liabilities:		
Other debt investments	-	-	Long-term borrowings	2,761,890,000.00	2,220,000,000.00
Debt investments	-	-	Bonds payable	4,689,347,320.45	4,500,000,000.00
Long-term receivables	-	-	Long-term payables	-	-
Other equity instruments investments	-	-	Including: Long-term payables	-	-
Long-term equity investments	15,286,242,736.83	15,210,729,627.80	Special payables	-	-
Investment properties	-	-	Long-term employee remuneration payable	-	330,550,000.00
Other non-current financial assets	-	6,000,000.00	△Deferred revenue	-	-
Fixed assets	3,120,306.44	3,252,759.86	Estimated liabilities	-	-
Including: Disposal of fixed assets	-	-	Deferred income tax liabilities	32,247.35	32,247.35
Right-of-use assets	21,850,091.84	21,850,091.84	Lease liabilities	-	12,111,653.04
Construction in progress	-	-	Other non-current liabilities	-	-
Biological assets for production	-	-	Including: Special reserve	-	-
Oil and gas assets	-	-	Total non-current liabilities	7,451,269,567.80	7,062,693,900.39
Intangible assets	46,006.31	80,511.02	Total liabilities	23,692,384,140.57	23,603,879,116.20
Including: Land use right	-	-	Owners' equity (or shareholders' equity):		
Development expenses	-	-	Paid-in capital (equity)	15,000,000,000.00	15,000,000,000.00
Goodwill	-	-	State-owned capital	-	-
Long-term deferred expenses	-	-	Collective capital	-	-
Deferred income tax assets	329,076.78	329,076.78	Legal person capital	15,000,000,000.00	15,000,000,000.00
Other non-current assets	3,776,968.08	23,674,779.75	Including: State-owned legal person capital	15,000,000,000.00	15,000,000,000.00
Including: Contract assets	-	-	Collectively-owned legal person capital	-	-
			Individual's capital	-	-
			Foreign capital	-	-
			Other equity instruments	-	-
			Capital surplus	34,472,792.11	34,472,792.11
			Less: treasury shares	-	-
			Other comprehensive income	20,900,416.58	20,900,416.58
			Including: Differences on translation of foreign currency statements	-	-
Total non-current assets	15,315,365,186.28	15,265,916,847.05	Surplus reserves	823,024,266.76	823,024,266.76
			Special reserves	-	-
			Undistributed profits	240,030,831.11	139,719,503.05
			Total equity attributable to owners of the parent company	16,118,428,306.56	16,018,116,978.50
			△Minority interests	-	-
Total assets	39,810,812,447.13	39,621,996,094.70	Total owners' equity	16,118,428,306.56	16,018,116,978.50
			Total liabilities and owners' equity	39,810,812,447.13	39,621,996,094.70

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF PROFIT OR LOSS IN ACCORDANCE WITH THE
PRC STANDARDS MARCH 2023

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Operating revenue	-	-
Including: Revenue from principal businesses	-	-
Revenue from other businesses	-	-
II. Operating costs	-	-
Including: Costs for principal businesses	-	-
Costs for other businesses	-	-
Tax and surcharge	10,063.48	106,235.63
Selling expenses	-	-
Management expenses	33,039,719.44	22,058,979.63
Including: Entertainment expenses	43,211.14	23,544.70
Research and development expenses	264,150.94	1,061,823.92
Finance costs	-61,415,464.07	-57,862,451.61
Including: Interest expenses	87,399,877.13	41,312,039.88
Interest income	20,695,013.46	65,765,497.45
Net Loss from exchange (net gain is represented by “-”)	-128,122,435.24	-35,952,030.12
Other revenue	177,799.90	232,321.35
Gain from investment (loss is represented by “-”)	71,853,109.03	41,728,494.93
Including: Gains from investment in associates and joint ventures	71,853,109.03	40,640,793.35
Net gains from hedging exposure (loss is represented by “-”)	-	-
Add: gains from changes in fair values (loss is represented by “-”)	178,888.92	-
Impairment losses of assets	-	-
Loss on credit impairment	-	-
Gains from disposal of assets	-	-
III. Operating profits (loss is represented by “-”)	100,311,328.06	76,596,228.71
Add: Non-operating income	-	-
Including: Gains from exchanging non-monetary assets	-	-
Government subsidies	-	-
Less: Non-operating expenses	-	-
Including: Loss on exchanging non-monetary assets	-	-
IV. Total profits (total loss is represented by “-”)	100,311,328.06	76,596,228.71
Less: Income tax expenses	-	11,900,577.37
V. Net profits (net loss is represented by “-”)	100,311,328.06	64,695,651.34
Including: Net gains of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	100,311,328.06	64,695,651.34
* Gains and losses of minority interests	-	-
Profit attributable to holders of perpetual capital instruments		

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF CASH FLOWS IN ACCORDANCE WITH THE PRC
STANDARDS MARCH 2023

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	-	-
Refund of taxes and levies	188,467.89	232,321.35
Cash received relating to other operating activities	4,118,145.94	1,112,928.71
Sub-total of cash inflows from operating activities	4,306,613.83	1,345,250.06
Cash paid for goods purchased and services received	-	76,938.24
Cash paid to and for employees	38,004,027.23	33,148,998.07
Payments of all types of taxes	92,947.09	20,379,191.51
Cash payments relating to other operating activities	71,866,899.53	15,272,366.85
Sub-total of cash outflows from operating activities	109,963,873.85	638,877,494.67
Net cash flow from operating activities	-105,657,260.02	-67,532,244.61
II. CASH FLOW FROM INVESTING ACTIVITIES:		
Cash received from investment recovery	4,720,000,000.00	3,800,000,000.00
Cash received from returns on investments	-	71,978,037.65
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	-	-
Net cash received from disposals of subsidiaries and other operating units	-	-
Cash received relating to other investing activities	-	-
Sub-total of cash inflows from investing activities	4,720,000,000.00	3,871,978,037.65
Cash paid to acquire fixed assets, intangible assets and other long-term assets	-	-
Cash paid for investments	4,723,660,000.00	4,245,832,600.00
Net cash paid for acquisition of subsidiaries and other operational units	-	-
Cash payments relating to other investing activities	-	-
Sub-total of cash outflows from investing activities	4,723,660,000.00	4,245,832,600.00
Net cash flow from investing activities	-3,660,000.00	-373,854,562.35
III. Cash flow from financing activities:		
Cash received from capital contribution	-	-
Including: Cash received by subsidiaries from investments of minority shareholders	-	-
Cash received from borrowings	4,500,000,000.00	-
Cash received from issuance of bonds	-	2,000,000,000.00
Cash payments relating to other financing activities	990,287,241.79	686,001,646.83
Sub-total of cash inflows from financing activities	5,490,287,241.79	2,686,001,646.83
Cash payments for debts settlement	4,443,800,000.00	2,000,000,000.00
Cash payments for distribution of dividends, profits, or interest expenses	95,032,371.12	13,345,147.49
Including: Dividends and profits paid by subsidiaries to minority shareholders	-	-
Cash payments relating to other financing activities	793,173,434.00	784,917,600.00
Sub-total of cash outflows from financing activities	5,332,005,805.12	2,798,262,747.49
Net cash flow from financing activities	158,281,436.67	-112,261,100.66
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-36.67	-10.68
V. Net increase in cash and cash equivalents	48,964,139.98	-553,647,918.30
Add: Opening balance of cash and cash equivalent	707,909,890.75	1,993,194,927.07
VI. Closing balance of cash and cash equivalents	756,874,030.73	1,439,547,008.77

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
(CONSOLIDATED) BALANCE SHEET IN ACCORDANCE WITH
THE PRC STANDARDS MARCH 2023**

Adjusted to denominated currency

Unit: RMB1

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	26,384,129,240.34	21,460,236,350.26	Short-term borrowings	48,422,294,536.45	34,043,085,357.69
Held-for-trading financial assets	7,161,850,450.97	7,507,282,064.09	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	55,952,631,208.93	48,931,715,633.97
Notes receivable	848,915,624.22	1,282,351,620.85	Including: Notes payable	13,673,992,479.62	13,235,861,940.44
Accounts receivable	70,113,224,044.82	59,752,772,739.51	Accounts payable	42,278,638,729.31	35,695,853,693.53
Financing receivables	30,099,209,465.09	23,791,412,577.67	Receipts in advance	536,543.13	-
Prepayment	6,795,067,497.64	4,944,535,854.76	Contract liabilities	5,295,026,337.69	3,537,167,833.02
Other receivables	5,299,706,088.04	4,963,029,014.18	Staff remuneration payable	2,735,793,703.95	2,865,645,825.32
Including: Interest receivable	626,827.45	357,405.21	Including: Wages payable	702,880,478.24	837,252,195.56
Dividends receivable	-	-	Benefits payable	333,746.78	-
Inventory	31,372,453,194.44	26,512,656,200.39	Taxation payable	1,556,757,124.81	1,693,928,606.44
Including: Raw materials	3,227,180,146.55	2,001,565,703.09	Including: Tax payable	1,432,081,628.47	1,544,713,458.18
Goods in stock (finished products)	25,447,550,401.18	22,046,761,578.67	Other payables	32,214,175,863.15	33,920,717,774.06
Contract assets	21,372,121.24	20,902,554.50	Including: Interest payable	8,476,187.85	19,660,293.28
Assets held for sale	45,537,620.87	45,537,620.87	Dividends payable	4,764,210,038.04	4,742,559,196.26
Non-current assets due within one year	10,759,953.36	230,474,654.69	Insurance contract liabilities	-	-
Other current assets	1,062,532,934.18	949,308,138.08	Liabilities held for sale	-	-
			Non-current liabilities due within one year	4,656,369,930.32	2,425,355,671.25
			Other current liabilities	573,522,977.02	680,314,002.07
Total current assets	179,214,758,235.21	151,460,499,389.85	Total current liabilities	151,407,108,225.45	128,097,930,703.82
Non-current assets:			Non-current liabilities:		
Other debt investments			Long-term borrowings	3,644,103,089.98	4,541,902,620.38
Debt investments	-	-	Bonds payable	4,689,347,320.45	4,500,000,000.00
Long-term receivables	1,012,439,354.08	868,639,562.04	Long-term payables	205,979,428.71	202,670,546.43
Other equity instruments investments	79,516,350.97		Including: Long-term payables	4,339,529.34	4,339,529.35
Long-term equity investments	5,136,690,189.72	5,017,241,596.34	Special payables	201,639,899.37	198,331,017.08
Investment properties	312,908,956.49	276,177,811.18	Long-term employee remuneration payable	487,099,355.27	828,947,832.23
Other non-current financial assets	904,019,071.49	711,830,602.64	Deferred revenue	985,020,858.64	775,139,183.18
Fixed assets	15,919,467,880.16	14,625,213,855.41	Estimated liabilities	60,283,752.46	25,591,135.89
Including: Disposal of fixed assets	7,010,792.41	6,954,460.97	Deferred income tax liabilities	1,713,656,438.24	1,477,912,561.45
Right-of-use assets	1,252,397,503.8	1,187,149,842.15	Lease liabilities	856,421,595.08	760,857,575.63
Construction in progress	2,229,695,101.67	2,007,929,961.98	Other non-current liabilities	39,149,889.26	973,637.93
Including: construction materials	-	-	Including: Special reserve	-	-
Biological assets for production	18,104,716.55	14,124,727.44	Total non-current liabilities	12,681,061,728.09	13,113,995,093.12
Oil and gas assets	-	-	Total liabilities	164,088,169,953.54	141,211,925,796.94
Intangible assets	10,660,040,786.46	9,608,588,725.17			
Including: Land use right	3,542,787,369.21	3,119,279,490.25	Paid-in capital (equity)	15,000,000,000.00	15,000,000,000.00
Development expenses	1,405,404,208.48	1,187,653,041.05	State-owned capital		
Goodwill	21,611,526,068.09	20,409,178,475.23	Collective capital		
Long-term deferred expenses	398,853,019.07	382,724,511.98	Legal person capital	15,000,000,000.00	15,000,000,000.00
Deferred income tax assets	1,676,998,841.69	1,403,146,719.07	Including: State-owned legal person capital	15,000,000,000.00	15,000,000,000.00
Other non-current assets	741,610,909.79	3,200,414,708.64	Collectively-owned legal person capital		
Including: Contract assets	143,333,666.7	144,562,622.12	Individual's capital		
			Foreign capital		
			Capital surplus	828,405,644.13	684,984,441.90
			Less: treasury shares	-	-
			Other comprehensive income	48,651,835.27	51,232,170.86
			Including: Differences on translation of foreign currency statements	40,840,808.17	43,412,428.77
			Surplus reserves	597,938,830.76	597,938,830.75
			Special reserves	2,546,033.17	2,056,429.35
			Undistributed profits	13,229,528,666.00	11,944,432,635.87
Total non-current assets	63,359,672,958.51	60,900,014,140.32	Total equity attributable to owners of the parent company	29,707,071,009.33	28,280,644,508.73
			△Minority interests	48,779,190,230.85	42,847,943,224.50
			Total owners' equity	78,486,261,240.18	71,128,587,733.23
Total assets	242,574,431,193.72	212,360,513,530.17	Total liabilities and owners' equity	242,574,431,193.72	212,340,513,530.17

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
(CONSOLIDATED) STATEMENT OF PROFIT OR LOSS IN ACCORDANCE WITH
THE PRC STANDARDS MARCH 2023**

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Operating revenue	60,549,929,362.59	51,023,315,329.18
Including: Revenue from principal businesses	60,029,852,186.95	50,606,470,432.56
Revenue from other businesses	520,077,175.65	416,844,896.62
II. Operating costs	50,251,436,013.89	42,769,459,554.85
Including: Costs for principal businesses	49,965,586,141.08	42,541,774,027.34
Costs for other businesses	285,849,872.81	227,685,527.51
Tax and surcharge	248,033,819.21	216,392,673.83
Selling expenses	4,426,123,806.66	3,664,285,625.61
Management expenses	1,328,847,312.68	1,108,412,847.95
Including: Entertainment expenses	20,076,392.41	15,371,014.67
Research and development expenses	371,171,483.28	295,950,622.16
Finance costs	376,703,357.22	340,281,804.89
Including: Interest expenses	569,935,171.62	450,682,102.02
Interest income	96,392,668.40	99,221,777.17
Net Loss from exchange (net gain is represented by “-”)	-128,858,621.96	-34,496,518.15
Other revenue	79,140,305.25	85,964,367.09
Gain from investment (loss is represented by “-”)	100,515,975.02	54,076,004.89
Including: Gains from investment in associates and joint ventures	121,926,290.29	74,730,104.97
Net gains from hedging exposure (loss is represented by “-”)		
Add: gains from changes in fair values (loss is represented by “-”)	51,533,760.24	22,722,235.24
Impairment losses of assets	24,048,133.36	22,583,469.24
Loss on credit impairment	279,270,685.03	288,608,368.79
Gains from disposal of assets	4,417,615.61	1,735,216.93
III. Operating profits (loss is represented by “-”)	3,479,902,407.39	2,481,838,186.02
Add: Non-operating income	13,541,640.02	8,656,319.89
Including: Gains from exchanging non-monetary assets	-	-
Government subsidies	160,500.00	44,216.00
Less: Non-operating expenses	12,549,034.74	11,763,604.74
Including: Loss on exchanging non-monetary assets		
IV. Total profits (total loss is represented by “-”)	3,480,895,012.67	2,478,730,901.17
Less: Income tax expenses	700,072,899.57	532,154,555.46
V. Net profits (net loss is represented by “-”)	2,780,822,113.10	1,946,576,345.72
Including: Net gains of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	1,263,188,228.44	925,716,852.92
* Gains and losses of minority interests	1,485,683,884.66	1,020,859,492.80
Profit attributable to holders of perpetual capital instruments	31,950,000.00	-

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
(CONSOLIDATED) STATEMENT OF CASH FLOWS IN ACCORDANCE WITH
THE PRC STANDARDS MARCH 2023**

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	54,344,401,484.28	49,071,392,538.87
Refund of taxes and levies	89,961,797.00	32,470,002.61
Cash received relating to other operating activities	3,211,013,993.66	3,565,624,481.42
Sub-total of cash inflows from operating activities	57,645,377,274.94	52,669,487,022.90
Cash paid for goods purchased and services received	51,547,385,718.49	46,095,276,272.51
Cash paid to and for employees	3,495,379,012.33	3,095,840,474.62
Payments of all types of taxes	2,375,112,076.13	2,047,174,004.52
Cash payments relating to other operating activities	6,397,763,580.13	6,261,281,531.37
Sub-total of cash outflows from operating activities	63,815,640,387.08	57,499,572,283.02
Net cash flow from operating activities	(6,170,263,112.14)	(4,830,085,260.12)
II. CASH FLOW FROM INVESTING ACTIVITIES:		
Cash received from investment recovery	2,634,654,230.74	3,914,775,626.48
Cash received from returns on investments	19,970,430.90	93,220,969.82
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	3,240,373.46	1,066,342.07
Net cash received from disposals of subsidiaries and other operating units	2,897,455.61	-
Cash received relating to other investing activities	3,250,726.48	4,757,500.04
Sub-total of cash inflows from investing activities	2,664,013,217.19	4,013,820,438.41
Cash paid to acquire fixed assets, intangible assets and other long-term assets	528,663,079.82	504,193,501.87
Cash paid for investments	3,080,033,383.51	4,205,100,000.00
Net cash paid for acquisition of subsidiaries and other operational units	-1,243,235,926.12	5,265,705.33
Cash payments relating to other investing activities	79,950.00	-
Sub-total of cash outflows from investing activities	2,365,540,487.21	4,714,559,207.20
Net cash flow from investing activities	298,472,729.98	-700,738,768.79
III. Cash flow from financing activities:		
Cash received from capital contribution	277,050,000.00	33,265,000.00
Including: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings	29,946,040,860.48	31,572,151,368.12
Cash received from issuance of bonds	-	2,000,000,000.00
Cash payments relating to other financing activities	5,888,824,175.31	4,090,987,851.26
Sub-total of cash inflows from financing activities	36,111,915,035.79	37,696,404,219.38
Cash payments for debts settlement	21,726,218,902.61	28,811,823,392.03
Cash payments for distribution of dividends, profits, or interest expenses	626,500,035.98	495,923,224.71
Including: Dividends and profits paid by subsidiaries to minority shareholders	-	-
Cash payments relating to other financing activities	4,171,384,075.55	3,785,075,271.21
Sub-total of cash outflows from financing activities	26,524,103,014.14	33,092,821,887.94
Net cash flow from financing activities	9,587,812,021.65	4,603,582,331.44
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-1,873,772.53	-1,762,191.97
V. Net increase in cash and cash equivalents	3,714,147,866.96	-929,003,889.44
Add: Opening balance of cash and cash equivalent	15,139,972,048.18	14,321,098,931.85
VI. Closing balance of cash and cash equivalents	18,854,119,915.14	13,392,095,042.41